TRPC6 and glomerulosclerosis: One important drug target are TRPC6 channels which are physiologically activated by DAG after Gq protein-mediated stimulation of PLCβ and which play a major pathophysiological role in many diseases, including glomerulosclerosis and pulmonary hypertension50.